The FDA has approved the first PET imaging drug in the United States for glioma, giving neuro-oncologists a tool aimed at one of the most agonizing uncertainties in brain cancer care: whether a suspicious spot on a follow-up scan is the tumor coming back or the aftermath of treatment.
Telix announced the approval of Pixclara, generically floretyrosine F 18, on Monday. The drug is indicated for use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients one month of age and older.
-copy-dd1f2bf0.jpeg?w=600)
